Altria's Third Quarter Tests Whether OnPlus Can Revive Oral Tobacco As Street Eyes Guidance Top

Altria heads into its third-quarter report with a stronger hand than it held three months ago, and a more demanding audience. Last quarter management raised the low end of its full-year earnings range, pointed to a fourth straight quarter of moderating cigarette declines, and laid out a string of second-half catalysts. The open question is whether those catalysts, particularly the national push behind OnPlus nicotine pouches, are starting to show up in the numbers or remain promises for 2027.

Wall Street expects adjusted earnings of $1.51 per share, up 4.1% from $1.45 a year ago, with the Earnings Whisper slightly higher at $1.53. That gap is small, but it suggests some appetite for a modest beat rather than a clean in-line print. Revenue is forecast at $5.30 billion, a 12.7% drop that looks far steeper than the roughly 5% industry volume decline management described. For a business that has long relied on pricing to offset shrinking volumes, earnings per share remains the better gauge of health, and on that score this is a quarter of steady, mid-single-digit growth rather than acceleration.

The guidance math is where the bar gets interesting. Altria now expects 2026 earnings of $5.61 to $5.72 per share, narrowed from $5.56 to $5.72. Consensus sits at $5.70, near the top of that range. First-half earnings grew 4.9%, and the Street is effectively betting the second half grows a bit faster. Management has flagged reasons that could happen, notably a duty drawback benefit expected to build in the back half and split more evenly between the third and fourth quarters. If that refund shows up meaningfully now, it supports the high end. If it slips toward the fourth quarter, the third quarter could look soft even with the full-year story intact.

Oral tobacco is the segment most likely to move sentiment. Adjusted operating income there fell 8% last quarter as volume dropped 8.5%, hurt by a tough comparison against a year when a competitor had supply problems, and by spending to get OnPlus into consumers' hands. OnPlus gained 0.8 point of retail share sequentially, but volume has not clearly inflected since the March national launch. With the 12mg national expansion slated for this quarter, a validating report would show stabilizing segment income and visible share momentum. Another sharp decline with little to show for the investment would challenge the idea that Altria can build a credible pouch franchise.

In smokables, the bull case rests on continued moderation in cigarette declines, helped by enforcement against illicit vapes, and on margins holding near the 64.8% posted last quarter despite added spending on the value-oriented Marlboro Cowboy Cut. The risk is the consumer. Discount brands gained 2.6 points of share while Marlboro lost 1.5 points, and the Basic brand faces tougher comparisons as its repositioning laps. Faster trade-down would squeeze the pricing engine. Cigars and the ABI stake, where equity earnings rose 21.5% last quarter, offer some cushion.

The market has grown warmer. Sentiment has climbed to 40.6% bullish from 16.5% before the last report, and shares have gained 5.6% since then, edging past the S&P 500. At $74.64, the stock trades well above its 200-day average of $68.13 and within about 1.5% of its post-earnings high of $75.74, approaching a breakout, though still below the prior quarter's peak near $77. That positioning leaves less room for disappointment. Ultimately the report hinges on whether Altria can show the second-half lift it promised, through the drawback benefit and early OnPlus traction, without sacrificing smokable margins to a stretched consumer.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It was generated automatically, with the help of AI, from Earnings Whispers and company data, and checked by Earnings Whispers before publication.